Zhonghua Gan Zang Bing Za Zhi [JOURNAL]
Sun
200 papers
[Transitional and clinical practice pathways for whole-course management of hepatocellular carcinoma in the infectious diseases department].
Tao YC, Lei XZ, Zhou TY … +3 more , Lu JJ, Zhou LY, Chen EQ
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373443 · Full text
Abstract loading — click title to view on PubMed.
[Natural history and risk factors of metabolic associated fatty liver disease in Chinese cohorts].
Zhang J, Zhan RX, Wang Y … +1 more , Nan YM
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373442 · Full text
Metabolic associated fatty liver disease (MAFLD) has become the most common chronic liver disease in China, yet a comprehensive review of the natural history of disease progression and its risk factors is still lacking....
Metabolic associated fatty liver disease (MAFLD) has become the most common chronic liver disease in China, yet a comprehensive review of the natural history of disease progression and its risk factors is still lacking. This review evaluates integrated natural history characteristics and key risk factors from Chinese cohort studies of MAFLD. In the MAFLD cohorts, the incidence rate of liver fibrosis progression was 19.2%-38.4% over 3-6 years. The hepatocellular carcinoma incidence rate was 0-2.7% over 6-11 years. The all-cause mortality rate was 2.0%-12.0% over 4.6-10 years. Diabetes and abnormal blood glucose were strong predictors of disease progression, and overweight and obesity, hypertension, and age were other risk factors. The article suggests that MAFLD can progress rapidly in certain Chinese cohorts, with multiple risk factors driving the course of the disease. Future large-scale prospective studies are necessary to clarify the mechanisms and optimize intervention strategies.
[Analyzing research advances in single-cell sequencing technology for immunopathological mechanisms in acute-on-chronic liver failure].
Zang SX, Cui CJ, Cui J … +3 more , Zhang YL, Fu N, Nan YM
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373441 · Full text
Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized by acute deterioration of liver function on the basis of chronic liver disease, primarily manifested as liver and/or extrahepatic organ failure....
Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized by acute deterioration of liver function on the basis of chronic liver disease, primarily manifested as liver and/or extrahepatic organ failure. Due to its rapid progression and poor prognosis, ACLF poses a serious threat to the patient's life. The pathogenesis process of ACLF is extremely complex, with overactivation and dysregulation of the immune system playing key roles in disease development. The high heterogeneity and complexity of immune cells have limited systematic understanding of the disease mechanisms and hindered the development of new therapies. The rise of single-cell sequencing technology has enabled the exploration of gene expression profiles at the single-cell level with high resolution, offering significant application value in analyzing the immune microenvironment and pathogenesis of ACLF, thereby helping to promote the exploration and development of new treatment methods. This review summarizes recent key advances in the application of single-cell sequencing technology in ACLF research, providing a theoretical basis for clarifying the pathogenesis and developing novel targeted treatment strategies.
[Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].
Lu XL, Xu WC, Ke HR … +3 more , Cheng QH, Li BL, Chen JJ
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373440 · Full text
Effective antibiotic treatment is crucial for patients with severe liver disease combined with bacterial infections in the early stage. However, the incidence rate of multidrug-resistant bacteria (MDROs) infection in suc...
Effective antibiotic treatment is crucial for patients with severe liver disease combined with bacterial infections in the early stage. However, the incidence rate of multidrug-resistant bacteria (MDROs) infection in such patients is as high as 34%, and it is increasing year by year, becoming one of the main causes of antibiotic treatment failure and patient mortality. The main common MDROs in clinical practice are methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus, and extended-spectrum β-lactamase-producing Enterobacteriaceae, with limited antimicrobial therapeutic options. Therefore, research on the diagnosis and treatment of MDRO infection can significantly improve the prognosis of patients with severe liver disease. The main risk factors for MDRO infections in these patients include frequent hospitalizations, invasive procedures, MDRO colonization, and repeated exposure to antimicrobial agents. The key measures to reduce MDRO infection are to strengthen nosocomial infection control, use antimicrobial agents rationally, conduct epidemiological surveillance, and actively screen colonized patients.
[Dietary serine supplementation inhibits the hepatic macrophage AKT/mTOR pathway and improves primary biliary cholangitis].
Ran Y, Yuan W, Jia H … +9 more , Wang XY, Liu RY, Li JW, Han ZZ, Shen M, Yang H, Wang SR, Wang BM, Zhou L
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373439 · Full text
To investigate the correlation between serum serine levels and the degree of severity of primary biliary cholangitis (PBC) so as to elucidate the protective effect and molecular mechanism of serine supplementation in cho...
To investigate the correlation between serum serine levels and the degree of severity of primary biliary cholangitis (PBC) so as to elucidate the protective effect and molecular mechanism of serine supplementation in cholestatic liver disease. Serum serine levels were measured in 62 cases with PBC patients diagnosed at Tianjin Medical University General Hospital from January 2021 to June 2023, and their correlation with serological indicators and liver pathological scores was analyzed. A C57BL/6J mouse model of cholestatic liver injury was established by inducing a 0.1% dimethylnitrosamine (DDC) diet. Serum biochemical indicators, hepatic inflammatory factor mRNA expression, liver histopathological changes, macrophage M1 polarization marker (CD86), and protein expression in the protein kinase B/mammalian target of rapamycin (AKT/mTOR) pathway were intervened through dietary serine supplementation. experiments were conducted by stimulating RAW264.7 macrophages with lipopolysaccharide (LPS) to observe the effects of serine on inflammatory factors, M1 polarization, and the AKT/mTOR pathway. Intergroup comparisons for measurement data were performed using independent sample t-tests or Wilcoxon rank-sum tests. Correlations between serum serine levels and the above serological indicators and liver pathological scores were analyzed using Pearson or Spearman methods. Serum serine levels were significantly negatively correlated with alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (γ-glutamyltransferase), total bilirubin, immunoglobulin G, and liver pathological scores in patients with PBC (<0.05). Dietary serine supplementation significantly improved cholestasis in DDC mice, inhibited the expression of hepatic tumor necrosis factor-α, interleukin-1β, and interleukin-6 mRNA (<0.05), reduced portal inflammatory infiltration, and decreased CD86⁺M1 macrophage infiltration and p-AKT/p-mTOR co-localization (<0.05). In vitro experiments showed that serine intervention inhibited lipopolysaccharide-induced macrophage M1 polarization and inflammatory cytokine expression and downregulated p-AKT/p-mTOR protein expression (<0.05). Reduced serum serine levels are associated with the degree of severity of PBC. Dietary serine supplementation can inhibit the hepatic macrophage AKT/mTOR signaling pathway and block M1 polarization and inflammatory responses, thereby improving cholestatic liver injury.
[Clinical study on the efficacy of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia patients with chronic hepatitis B].
Zhao SX, Ren WG, Yang MB … +5 more , Chi XL, Xiao HM, Ma SP, Jia P, Nan YM
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373438 · Full text
To comprehensively evaluate the efficacy and safety profile of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia in chronic hepatitis B. A randomized, controlled, multicenter cl...
To comprehensively evaluate the efficacy and safety profile of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia in chronic hepatitis B. A randomized, controlled, multicenter clinical trial was conducted. One hundred patients with low-level viremia in chronic hepatitis B admitted between December 2021 and March 2024 were randomly divided into an experimental group and a control group, with 50 cases in each group. The experimental group received nucleos(t)ide analogues combined with Wuling capsules, while the control group received nucleos(t)ide analogues alone. Of the 100 subjects, 96 in the full analysis set (FAS) (experimental group: 47; control group: 49) were included for statistical analysis. Changes in hepatitis B virus (HBV) DNA levels, serological markers of hepatitis B, liver function parameters, and clinical symptom scores were compared following 180 days of treatment between the two groups. Categorical data were analyzed using the test, with results expressed as percentages (%). Quantitative data were expressed as mean ± standard deviation (x¯±) for normally distributed datasets and analyzed using the -test. The Wilcoxon rank-sum test was used for non-normally distributed data. The HBV DNA seroconversion rate was significantly higher in the experimental group compared to the control group [67.39% (31/46) vs. 48.98% (24/49), =6.65, <0.05], while HBsAg, HBeAg, and anti-HBc were all lower in the experimental group than the control group (<0.05) following 180 days of treatment. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin were all significantly higher in the experimental group than in the control group [(24.17±10.07) U/L vs. (30.77±19.00) U/L, (23.70±6.58) U/L vs. (27.66±10.46) U/L, and (12.69±5.72) μmol/L vs. (15.36±5.90) μmol/L, <0.05]. The normalization rates of ALT, AST, and γ-glutamyl transferase were significantly higher in the treatment group than those in the control group (85.71% vs. 66.67%, 83.33% vs. 60.00%, and 100% vs. 66.67%, <0.05). The visual analogue scale (VAS) scores and clinical symptom scores were also superior in the treatment group to those in the control group (<0.01 or <0.05). The main symptoms of patients, including hypochondriac pain, belching, and anorexia, were significantly improved in the treatment group compared to the control group (<0.05 or <0.01). No adverse reactions related to Wuling Capsules were found. Wuling capsules combined with nucleos(t)ide analogues achieved significant efficacy in treating low-level viremia patients with chronic hepatitis B. This treatment significantly improved HBV DNA seroconversion rate, hepatitis B blood markers, liver function levels, and clinical symptoms, with a favorable safety profile.
[Study on preoperative prediction of microvascular invasion based on contrast-enhanced ultrasound habitat imaging combined with peritumoral radiomics in hepatocellular carcinoma].
Wei XX, Tang QQ, Pang JS … +2 more , He Y, Yang H
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373437 · Full text
Hepatocellular carcinoma has a poor prognosis, and microvascular invasion (MVI) is an important indicator for guiding surgical decisions and influencing long-term survival. This study aims to explore the application valu...
Hepatocellular carcinoma has a poor prognosis, and microvascular invasion (MVI) is an important indicator for guiding surgical decisions and influencing long-term survival. This study aims to explore the application value of habitat imaging combined with peritumoral radiomics in the preoperative assessment of MVI based on contrast-enhanced ultrasound (CEUS) images in hepatocellular carcinoma. The contrast-enhanced ultrasound images and clinical data of 186 patients with pathologically confirmed hepatocellular carcinoma at the First Affiliated Hospital of Guangxi Medical University were retrospectively analyzed and randomly divided into a training group (=130) and a test group (=56) in a 7∶3 ratio. Eleven clinical indicators, such as patient age and alpha-fetoprotein (AFP) were extracted. Microvascular invasion (MVI)-independent risk factors were screened to construct clinical prediction models for tumors. Peritumoral and intratumoral regions of interest (ROIs) were depicted at 5 mm and 10 mm on arterial and delayed CEUS phase images. Traditional radiomic features were extracted. Corresponding prediction models were constructed. The above-mentioned depicted intratumoral regions of interest were concurrently applied using K-means clustering to divide the tumor habitat subregions, habitat features, and establish an intratumoral habitat model. Furthermore, a combined model was constructed by integrating a habitat with 5 mm peritumoral features. The predictive efficacy of each model was comprehensively evaluated using indicators such as the area under the receiver operating characteristic (AUC), calibration curve, and decision curve. The clinical model had poorly performed predictions for MVI (training set AUC=0.762; validation set AUC=0.668). The 5 mm peritumoral radiomics model showed better generalization ability and stability than the 10 mm peritumoral and intratumoral models (training set AUC=0.785 . 0.786, 0.802; validation set AUC=0.727 . 0.672, 0.708). The intratumoral habitat model (training set AUC=0.824; validation set AUC=0.753) was more effective in predicting MVI than both the clinical and the traditional radiomics models in hepatocellular carcinoma. Furthermore, the predictive efficacy of MVI with the selection of a constructed intratumoral habitat combined with 5 mm peritumoral was improved (training set AUC=0.888; test set AUC=0.843), with accuracy, sensitivity, specificity, and clinical net benefit all significantly higher than those of other models. The classification ability had a positive improvement effect. Intratumoral habitat analysis can effectively assess the MVI status based on contrast-enhanced ultrasound in patients with hepatocellular carcinoma. In addition, the combined 5-mm peritumoral radiomics model can more accurately assess the MVI status in patients with hepatocellular carcinoma.
[Construction norms for the tiered diagnosis and treatment and standardized management center of metabolic-associated fatty liver disease].
Fatty Liver and Alcoholic Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373436 · Full text
This guideline aims to provide systematic guidance for establishing "Metabolic-Associated Fatty Liver Disease (MAFLD) Tiered Diagnosis, Treatment, and Standardized Management Centers" at various levels of medical institu...
This guideline aims to provide systematic guidance for establishing "Metabolic-Associated Fatty Liver Disease (MAFLD) Tiered Diagnosis, Treatment, and Standardized Management Centers" at various levels of medical institutions. Faced with the severe challenges of high prevalence and low diagnosis and treatment rates for this disease, the guidelines clarify the background, necessity, tiered setting standards, multidisciplinary collaboration models, and clinical diagnosis and treatment pathways for center construction. The core is to establish a standardized management framework and integrate multidisciplinary resources to achieve standardized management of the entire process, from screening, diagnosis, and treatment to long-term follow-up, thereby improving the overall prevention and control level in China and building a chronic disease prevention and control network and data platform for MAFLD.
[Clinical strategies and indication expansion of interventional ultrasonography ablative therapy for hepatic tumors].
Liang YG, Wang HY, Zhao QY … +1 more , Jiang TA
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373435 · Full text
Thermal ablation has become an important treatment option for early-stage hepatocellular carcinoma with the development of interventional ultrasound technology. However, in the treatment of medium-to-large-volume tumors,...
Thermal ablation has become an important treatment option for early-stage hepatocellular carcinoma with the development of interventional ultrasound technology. However, in the treatment of medium-to-large-volume tumors, intrahepatic cholangiocarcinoma, and high-risk anatomical sites, it still faces clinical bottlenecks such as high recurrence rates and difficulties with margin control. This article discusses current clinical difficulties and explores indication expansion and coping strategies for various ablation techniques. The "no touch" strategies of radiofrequency ablation and microwave ablation have shown an overall survival period that is comparable to that of surgery for medium or multiple tumors that are 3 to 5 cm in size. Microwave ablation and repeated surgical resection that meets the Milan criteria have similar overall and disease-free survival rates in patients with intrahepatic cholangiocarcinoma. Non-thermal ablation techniques such as irreversible electroporation offer safe alternatives for refractory lesions adjacent to large blood vessels or bile ducts due to their characteristics of no heat-sink effect and preservation of collagen scaffolds. Image fusion navigation and synergistic "ablation plus immunotherapy" may be key directions for overcoming local control bottlenecks and improving long-term prognosis in the future.
[Application and prospects of artificial intelligence from tool empowerment to paradigm reconstruction for whole-course diagnosis and treatment of liver diseases by ultrasound].
Huang JY, Xu QQ, Chen LD … +1 more , Wang W
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373434 · Full text
The research system and clinical decision-making pathways have been systematically reshaped as the application of artificial intelligence (AI) in the field of ultrasonically has become increasingly mature recently for li...
The research system and clinical decision-making pathways have been systematically reshaped as the application of artificial intelligence (AI) in the field of ultrasonically has become increasingly mature recently for liver disease imaging. Research focus has shifted at the clinical level from low-dimensional classification and diagnostic tasks to high-dimensional, task-driven intelligent diagnosis and treatment. The underlying algorithms are undergoing a profound transition at the technological level from single-modality to multi-modal collaboration and from isolated feature extraction to spatiotemporal sequential reasoning. Therefore, to provide a forward-looking analysis and reflection on future development trends and existing challenges, this article systematically reviews the latest research progress of AI in the field of liver disease in terms of four aspects of ultrasonography: early-stage screening, precise diagnosis, personalized treatment, and prognostic monitoring.
[Ultrasound technologies' new clinical application for chronic liver diseases].
Xiao MY, Lu X, Jin JY … +2 more , Wu ML, Ren J
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373433 · Full text
Chronic liver disease and its complications impose a heavy burden，and the limits of liver biopsy tests have rendered non-invasive assessment an urgent clinical need. Multiple novel parameters，such as elasticity，viscos...
Chronic liver disease and its complications impose a heavy burden，and the limits of liver biopsy tests have rendered non-invasive assessment an urgent clinical need. Multiple novel parameters，such as elasticity，viscosity，fat quantification，and micro-flow imaging，have been established as reliable methods for staging liver fibrosis，monitoring inflammatory activity，and quantifying steatosis，providing considerable potential for diagnosis，disease monitoring，and prognostic management of chronic liver diseases via ultrasonically technology at an early stage. Challenges such as the non-universal nature of diagnostic thresholds，interference from confounding factors，and a lack of technical standardization remain，despite the considerable value of each technology. Therefore，the integration of multiple parameters and artificial intelligence models may be a breakthrough direction in the future.
[Ultrasound technology's new application in the diagnosis and treatment of liver cancer].
Cai Q, Yu J
Zhonghua Gan Zang Bing Za Zhi · 2026 Jun · PMID 42373432 · Full text
Primary liver cancer (represented by hepatocellular carcinoma and intrahepatic cholangiocarcinoma) is a common clinical malignant liver tumor with a high mortality burden. The disease has high heterogeneity, and diagnosi...
Primary liver cancer (represented by hepatocellular carcinoma and intrahepatic cholangiocarcinoma) is a common clinical malignant liver tumor with a high mortality burden. The disease has high heterogeneity, and diagnosis stratification and efficacy evaluation heavily rely on imaging. Among imaging modalities, ultrasound, with its advantages of real-time imaging, gradually improving resolution, and dynamic assessment of multi-parameter information such as blood flow perfusion, is continuously expanding its application scenarios in the liver cancer diagnosis and treatment chain along with the rapid development of a series of new technologies. In recent years, technologies such as microvascular blood flow ultrasound, super-resolution ultrasound, three-dimensional multi-parameter contrast-enhanced ultrasound, viscoelasticity, and dispersive imaging have developed rapidly, enabling more refined acquisition of blood flow, perfusion, and mechanical information related to liver cancer. Simultaneously, workflow technologies such as integrated navigation and artificial intelligence-assisted procedures have promoted more precise and visual positioning, quantification, and evaluation during interventional procedures and provided a foundation for the further introduction of closed-loop simulation and decision support frameworks represented by digital twins. This article focuses on the two key aspects of liver cancer diagnosis and treatment, systematically reviews the above-mentioned ultrasound technologies' new clinical value and applicable scenarios and limitations, and looks forward to directions such as standardization, multi-center validation, and workflow integration, with the aim of providing a reference for clinical practice and research design.
[Research progress on cellular senescence and liver diseases].
Zhang LT, Hu JM, Wang JW … +2 more , Li H, Qin YJ
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209168 · Full text
Cellular senescence, a stable state of proliferative arrest induced by stressors such as telomere shortening and DNA damage, is often accompanied by a senescence-associated secretory phenotype (SASP) that is closely rela...
Cellular senescence, a stable state of proliferative arrest induced by stressors such as telomere shortening and DNA damage, is often accompanied by a senescence-associated secretory phenotype (SASP) that is closely related to the imbalance of liver homeostasis and the progression of chronic liver diseases. This article outlines the main phenotypes and signaling pathways of cellular senescence, reviews research progress on the senescence of different liver cell populations and the senescence-associated secretory phenotype in metabolic-associated fatty liver disease, viral hepatitis, liver fibrosis/cirrhosis, and hepatocellular carcinoma, discusses their "double-edged sword" effects at different etiologies and stages, and summarizes intervention strategies such as senolytic drugs and their potential in combination with antiviral, antifibrotic, and immunotherapy. Concurrently, it also points out needs still to be established unifying evaluation system and translatable biomarkers.
[Research progress on the pathogenesis and clinical treatment of cirrhotic cardiomyopathy].
Wang KY, Liu L
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209167 · Full text
Liver cirrhosis is often accompanied by cardiovascular lesions, including hyperdynamic circulatory states and myocardial lesions. The hyperdynamic circulatory state manifests as increased cardiac output, peripheral vasod...
Liver cirrhosis is often accompanied by cardiovascular lesions, including hyperdynamic circulatory states and myocardial lesions. The hyperdynamic circulatory state manifests as increased cardiac output, peripheral vasodilation, and decreased mean blood pressure. Cirrhotic cardiomyopathy involves impaired cardiac systolic and/or diastolic function, ventricular cavity enlargement or ventricular hypertrophy, and electrophysiological abnormalities. The pathogenesis of cirrhotic cardiomyopathy remains unclear, but gases such as nitric oxide, inflammatory factors, oxidative stress systems, apoptotic factors, sympathetic and parasympathetic nervous systems, endocannabinoid systems, and ion channels all play a role. The treatment of cirrhotic cardiomyopathy is primarily limited to animal studies; however, albumin has clinical therapeutic effectiveness.
[Pathophysiological mechanisms of coagulation dysfunction associated with liver disease].
Wang H, Chen X, Lu YY
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209166 · Full text
Coagulation abnormalities associated with liver diseases easily lead to spontaneous and secondary bleeding, which is associated with hemodynamic changes, reduced synthesis of coagulation factors, liver disease-related th...
Coagulation abnormalities associated with liver diseases easily lead to spontaneous and secondary bleeding, which is associated with hemodynamic changes, reduced synthesis of coagulation factors, liver disease-related thrombocytopenia, and pharmacological interventions. On the other hand, patients with liver disease also have a hypercoagulable state, making them prone to portal vein thrombosis, which is associated with hemodynamic changes, reduced synthesis of anticoagulants, abnormal vascular intima structure, inflammation, and pharmacological treatment. Additionally, patients with liver disease are at an intertwined risk of bleeding and thrombosis and are in a fragile state of hemostasis rebalancing for an extended period. Genetic factors and diagnostic and therapeutic procedures further challenge the management of coagulation function in patients with liver disease. This article discusses the mechanisms of coagulation abnormalities from the perspectives of both bleeding and thrombosis, providing assistance for dynamically managing and rebalancing the hemostasis in patients with liver disease.
[A case of acetaminophen-induced cholestatic liver injury accompanying severe hypercholesterolemia in children].
Chen L, Gao XY, Liu XY … +1 more , Shao YL
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209165 · Full text
Abstract loading — click title to view on PubMed.
[Analysis of familial intrahepatic cholestasis caused by ubiquitin-specific peptidase 53 gene mutation].
Wang H, Zheng X, Yu MM … +2 more , Yu ZD, Wang YS
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209164 · Full text
To investigate the clinical characteristics and gene mutation status of progressive familial intrahepatic cholestasis caused by a ubiquitin-specific peptidase 53 (USP53) gene mutation (USP53-FIC) in a family. A female i...
To investigate the clinical characteristics and gene mutation status of progressive familial intrahepatic cholestasis caused by a ubiquitin-specific peptidase 53 (USP53) gene mutation (USP53-FIC) in a family. A female infant patient with USP53-FIC and her family who presented to the Department of Gastroenterology, Children's Hospital Affiliated with Zhengzhou University, in May 2025 with a one-month history of jaundice and yellow urine, which worsened over a one-week period of ecchymosis, were selected as the study subjects. Peripheral blood samples were collected from the patient, her parents, and her elder brother for whole-exome sequencing of the family, followed by Sanger sequencing for validation. The patient was a 5-month-23-day-old female presenting primarily with jaundice of the skin and sclera, dark urine, and skin ecchymosis. Liver function tests indicated cholestasis, normal gamma-glutamyl transferase, and abnormal coagulation function. Whole-exome sequencing of the family revealed a compound heterozygous variant of c.1558C>T and c.829dup in the USP53 gene, inherited from her mother and father, respectively. Sanger sequencing confirmed that the patient's older brother carried the same variants. The c.1558C>T was previously reported as a pathogenic variant, while c.829dup was previously unreported. PVS1 + PM2_Supporting + PM3 was reported as a pathogenic variant according to the American Society for Medical Genetics and Genomics variant rating guidelines. The compound heterozygous variant c.1558C>T and c.829dup in the USP53 gene are the genetic cause of this USP53-FIC in a family. USP53-FIC should be suspected for infants who suddenly develop cholestasis accompanied by coagulation disorders but normal gamma-glutamyl transferase levels. Genetic testing is helpful in clarifying the diagnosis and guiding treatment. The c.829dup variant enriches the variant spectrum of the USP53 gene.
[Efficacy and safety profile of magnesium isoglycyrrhizate in patients with a ≤3 fold- elevation of the upper limit of normal transaminases: a multicenter, real-world retrospective study].
Liu LG, Yu J, Li ZZ … +2 more , Li LR, Xie W
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209163 · Full text
The clinical efficacy of magnesium isoglycyrrhizinate (MgIG) injection in patients with abnormal transaminase levels ≤3 times the upper limit of normal (ULN) was retrospectively study based on a real-world design. Data...
The clinical efficacy of magnesium isoglycyrrhizinate (MgIG) injection in patients with abnormal transaminase levels ≤3 times the upper limit of normal (ULN) was retrospectively study based on a real-world design. Data were collected from January 2016 to May 2024 at three research centers (The First Hospital of Hebei Medical University, Shanghai Eastern Hepatobiliary Surgery Hospital, and Nanfang Hospital of Southern Medical University) from patients with abnormal transaminase ≤3 times the ULN and assigned according to the treatment regimen into a monotherapy group (including MgIG and other conventional hepatoprotective drugs) and a control group (no hepatoprotective drugs were used). Baseline matching was performed. Efficacy was evaluated by changes in three biochemical indicator conditions: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBil) after seven days of treatment. The independent samples -test or Wilcoxon rank-sum test was used to analyze the comparison of continuous data between intergroups. The test or Fisher's exact test was used to compare inter-group categorical variables. A total of 501 cases were included, with a median age of 60 years. Males accounted for 69.9%. Cancer patients accounted for 72.5%. The baseline matching resulted in a 1∶1 group assignment. The results showed, following seven days of treatment: (1) Magnitude of reduction: ALT and TBil were significantly lower in the other conventional hepatoprotective drug groups than in the control group (<0.05), while ALT, AST, and TBil were significantly lower in the MgIG group than in the control group (<0.05). The reduction in ALT and AST was significantly higher in the MgIG group than in the other conventional hepatoprotective drug groups (<0.05). (2) Normalization rate response: The normalization rate of TBil was lower in other conventional hepatoprotective drug groups than that in the blank group (<0.05), while the normalization rate of AST was significantly higher in the MgIG group than that in the blank group (<0.05), and the normalization rates of ALT, AST, and TBil were all significantly higher in the MgIG group than those in other conventional hepatoprotective drug groups (58.7% . 40.0%, 74.7% . 49.3%, and 66.7% . 50.7%, respectively, <0.05). (3) Proportion of patients with a >50% decrease in the three indicators from baseline: There was no statistically significant difference between the other conventional hepatoprotective drug groups and the control group (>0.05), while the MgIG group had significantly higher ALT and AST levels than the control group and other conventional hepatoprotective drug groups (ALT: 45.9% . 31.1%, 53.3% . 38.5%, <0.05; AST: 50.0% . 24.0%, 54.7% . 30.0%, <0.001). (4) Safety profile assessment: There was no statistically significant difference between the MgIG group and other conventional hepatoprotective drug groups (>0.05). MgIG can rapidly, effectively, and safely improve liver function indicators in patients with abnormal transaminase elevations ≤ 3×ULN.
[Menstrual blood-derived mesenchymal stem cell transplantation improves anti-fibrosis mechanisms in mouse models of alcoholic liver fibrosis].
Yang C, Li A, Gao Y … +5 more , Wu MQ, Wei ZY, Cui JY, Xu ZY, Wu T
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209162 · Full text
To investigate the ameliorative effect of menstrual blood-derived mesenchymal stem cells (MenSCs) on liver fibrosis and injury, and further study whether it plays a role by regulating the Toll-like receptor (TLR) signali...
To investigate the ameliorative effect of menstrual blood-derived mesenchymal stem cells (MenSCs) on liver fibrosis and injury, and further study whether it plays a role by regulating the Toll-like receptor (TLR) signaling pathway in a mouse model of alcoholic liver disease (ALD). A C57BL/6J mouse model of ALD was established using the gradient ethanol gavage method combined with pyrazole. A blank control group and a model group were established. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) activities, as well as inflammatory factors, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), were measured. The modeling effect was evaluated by combining Masson staining and Sirius red staining in liver tissue with Western blotting to detect the protein expression of α-smooth muscle actin (α-SMA) and collagen type I α1 chain (COL1A1). Simultaneously, qPCR was used to detect the mRNA expression of TLRs and transforming growth factor β-activated kinase 1 (TAK1) to explore the related mechanisms. ALD model mice were divided into a phosphate-buffered saline (PBS) control group and a MenSCs treatment group [2×10⁵ MenSCs (200 μL) injected via tail vein], with intervention once a week sustained for four weeks after successful modeling. Mice batches were sacrificed on the seventh day following each intervention to collect serum and liver tissues. Collagen deposition changes were observed using Sirius red staining. The expression of α-SMA and transforming growth factor-β1 (TGF-β1) proteins was detected by Western blotting. Serum biochemical indicators levels were also measured. The effects of MenSCs on TLRs and TAK1 mRNA expression were assessed using qPCR to comprehensively evaluate the MenSCs intervention effect. The two groups were compared using paired -tests. Repeated measures analysis of variance (RM-ANOVA) combined with Tukey's multiple comparisons test was used for comparisons among multiple groups. Compared with the blank control group, serum levels of ALT, AST, and GGT, as well as inflammatory factors TNF-α and IL-6, were significantly elevated, while IL-1β levels were significantly decreased in the mouse model of the ALD group. Collagen deposition in liver tissue was markedly increased. The expression of fibrosis markers α-SMA and COL1A1 proteins was significantly upregulated (α-SMA: <0.001; COL1A1: <0.001). The mRNA expression of TLR1, TLR2, TLR4, TLR6, TLR7, and TLR8 was significantly upregulated, and the expression of TLR9 and TAK1 was downregulated, while the expression of TLR3 and TLR5 remained unchanged. Liver function levels (ALT and AST) were significantly reduced; liver fibrosis degree was markedly improved; and TGF-β1 and α-SMA protein expression were suppressed (TGF-β1: <0.001; α-SMA: =0.026) following MenSC transplantation in mice. MenSC specifically down-regulated the mRNA expression of TLR1, TLR2, TLR4, TLR6, TLR7, and TLR9, with significant inhibition of TLR1, TLR2, and TLR9 expression (<0.001), while TLR8 and TAK1 expression were not significantly affected at week 4 of intervention (>0.05). MenSCs transplantation can effectively improve liver function and reduce fibrosis in a mouse model of ALD, and its mechanism may be related to the inhibition of the TLR signaling pathway activation.
[An excerpt of the European Association for the Study of the Liver's clinical practice guidelines on liver vascular diseases in 2025].
Luo BH, Han GH
Zhonghua Gan Zang Bing Za Zhi · 2026 May · PMID 42209161 · Full text
Liver vascular diseases include portal vein thrombosis (with or without cirrhosis), portal-sinusoidal vascular disease, Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, non-obstructive sinusoidal dilatation...
Liver vascular diseases include portal vein thrombosis (with or without cirrhosis), portal-sinusoidal vascular disease, Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, non-obstructive sinusoidal dilatation and peliosis hepatis, visceral artery aneurysms, and hepatic arteriovenous fistulas. Importantly, with the exception of portal vein thrombosis in cirrhosis, the others are rare conditions. A substantial body of evidence has been published on the diagnosis, pharmacological treatment, and interventional therapy of liver vascular disorders since the European Association for the Study of the Liver issued the previous version of the clinical practice guidelines in 2016. These guidelines are based on a comprehensive review of relevant literature, providing recommendations for key clinical challenges and emphasizing implementation of individualized treatment by combining individual risk factors and clinical presentations. Thus, multidisciplinary collaborative management involving hepatologists, hematologists, pathologists, interventional radiologists, and surgeons is crucial in this field. The aim of this guideline is to provide guidance for the management of liver vascular diseases based on the best available evidence.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe